Aslan Pharmaceuticals LtdNASDAQ:ASLNNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.4470
- TODAY'S CHANGE (%)-0.0065 (-1.4333%)
- Bid / Lots0.4500/ 2
- Ask / Lots0.4600/ 19
- Open / Previous Close0.4500 / 0.4535
- Day Range
- 52 Week Range
- Volume99,019
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ASLN |
|---|---|---|
| 09:32 ET | 1166 | 0.45 |
| 09:36 ET | 300 | 0.4581 |
| 09:48 ET | 2500 | 0.458 |
| 10:03 ET | 10768 | 0.45 |
| 10:15 ET | 1350 | 0.4501 |
| 10:17 ET | 350 | 0.4503 |
| 10:21 ET | 100 | 0.4503 |
| 10:37 ET | 28488 | 0.4301 |
| 10:39 ET | 100 | 0.4301 |
| 10:48 ET | 100 | 0.4579 |
| 10:50 ET | 200 | 0.45 |
| 10:51 ET | 1398 | 0.44 |
| 10:53 ET | 400 | 0.4412 |
| 11:00 ET | 312 | 0.44 |
| 11:18 ET | 4485 | 0.4303 |
| 11:20 ET | 400 | 0.4303 |
| 11:22 ET | 100 | 0.4303 |
| 11:42 ET | 230 | 0.44 |
| 11:44 ET | 110 | 0.458 |
| 11:51 ET | 300 | 0.449 |
| 12:03 ET | 300 | 0.456 |
| 12:18 ET | 500 | 0.44 |
| 12:23 ET | 24988 | 0.456 |
| 12:25 ET | 500 | 0.455999 |
| 12:36 ET | 1100 | 0.44 |
| 12:38 ET | 500 | 0.4539 |
| 12:39 ET | 100 | 0.44 |
| 12:50 ET | 100 | 0.44 |
| 12:54 ET | 900 | 0.447 |
| 12:56 ET | 100 | 0.44 |
| 01:03 ET | 100 | 0.44 |
| 01:06 ET | 2000 | 0.4428 |
| 01:08 ET | 500 | 0.44 |
| 01:12 ET | 100 | 0.44 |
| 01:26 ET | 150 | 0.4411 |
| 01:33 ET | 700 | 0.44 |
| 01:42 ET | 100 | 0.44 |
| 02:02 ET | 200 | 0.44 |
| 02:33 ET | 100 | 0.44 |
| 02:36 ET | 100 | 0.44 |
| 02:40 ET | 100 | 0.44 |
| 02:44 ET | 600 | 0.447 |
| 02:45 ET | 100 | 0.44 |
| 03:14 ET | 1993 | 0.445 |
| 03:16 ET | 400 | 0.448 |
| 03:18 ET | 800 | 0.44 |
| 03:20 ET | 100 | 0.445 |
| 03:21 ET | 1800 | 0.44 |
| 03:23 ET | 100 | 0.44 |
| 03:25 ET | 1400 | 0.4519 |
| 03:27 ET | 200 | 0.44 |
| 03:30 ET | 100 | 0.44 |
| 03:32 ET | 100 | 0.44 |
| 03:36 ET | 100 | 0.44 |
| 03:39 ET | 100 | 0.44 |
| 03:56 ET | 621 | 0.4474 |
| 03:57 ET | 699 | 0.44 |
| 03:59 ET | 172 | 0.447 |
May 20, 2022
May 19, 2022
Asian ADRs Climb Higher in Thursday Trading, from 10:30AM ET on Thursday May 19, 2022 by MT Newswires
10:30AM ET on Thursday May 19, 2022 by MT Newswires
May 18, 2022
Asian ADRs Move Lower in Wednesday Trading, from 10:43AM ET on Wednesday May 18, 2022 by MT Newswires
10:43AM ET on Wednesday May 18, 2022 by MT NewswiresASLAN Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference, from 7:00AM ET on Wednesday May 18, 2022 by GlobeNewswire
7:00AM ET on Wednesday May 18, 2022 by GlobeNewswire
May 17, 2022
Asian ADRs Move Up in Tuesday Trading, from 11:08AM ET on Tuesday May 17, 2022 by MT Newswires
11:08AM ET on Tuesday May 17, 2022 by MT Newswires
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aslan Pharmaceuticals Ltd | 31.2M | -1.0x | --- |
Spruce Biosciences Inc | 31.7M | -0.7x | --- |
OncoSec Medical Inc | 30.3M | -0.7x | --- |
Oncorus Inc | 32.1M | -0.5x | --- |
Bioxytran Inc | 32.2M | -7.5x | --- |
NeuBase Therapeutics Inc | 32.3M | -1.0x | --- |
Company Information
ASLAN Pharmaceuticals Limited (ASLAN) is a clinical-stage immunology focused biopharmaceutical company. The Company is engaged in developing treatments to transform the lives of patients. The Company is focused developing ASLAN004, an antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, an oral inhibitor of dihydroorotate dehydrogenase (DHODH), which is being developed for autoimmune disease. ASLAN has a team in Menlo Park, California, and in Singapore, and conducts clinical development programs globally.
Contact Information
- Headquarters
- 83 Clemenceau Avenue, #12-03 Ue Square, Singapore 239920
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Andrew Howden
- Chief Executive Officer, Director
- Carl Firth
- Chief Operating Officer, Head of Finance
- Kiran Asarpota
- General Counsel
- Ben Goodger
- Chief Business Officer
- Stephen Doyle
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $31.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 13.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.41 |
EPS | $-0.44 |
Book Value | $-0.25 |
P/E Ratio | -1.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
